ChromaDex (CDXC)
(Delayed Data from NSDQ)
$2.75 USD
-0.13 (-4.51%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $2.74 -0.01 (-0.36%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum B VGM
Brokerage Reports
ChromaDex Corporation [CDXC]
Reports for Purchase
Showing records 1 - 20 ( 119 total )
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
2Q Preview - Expect Rev Growth and Encouraging Update on New Initiatives
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
NRC Receives Orphan Drug Designation From FDA
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Solid 1Q Results and Guidance Show Company On Solid Path to Profitability.
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top-Line In-Line, Modest Bottom-Line Beat; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
1Q24 Preview - Expecting A Good Start to 2024
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Recent Transactions Suggest Significant Hidden Value; Raising Price Target
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Beat; 2023 Financials; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Black Ink! Company Posts 1st Profitable Quarter Since Launch of Tru Niagen
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Solid 3Q Results, Cautious 4Q Guidance Points to Strong Growth in 2024
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top-Line Miss, Bottom-Line Beat; 3Q23 Financials; Reiterating Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Revenue In Line, Bottom-Line Beat; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R